Chemed opened higher at $545.01, compared with its previous close of $541.92. In the last trading session, the stock traded between $537.39 and $551.68. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Chemed is now worth
$ 112.23
giving a profit of
$ 12.23 (12.23%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
$-0.69 (-0.13%)
Day High
$551.68
Day Low
$537.39
Day Open
$545.01
Prev Close
$541.92
Volume
88,707
1W Return
4.03%
1M Return
5.71%
3M Return
0.39%
6M Return
27.67%
1Y Return
16.26%
Fundamentals
Market Cap ($ Mn)
7,074
PE Ratio
26.33
PB Ratio
8.26
PEG Ratio
19.81
ROE
23.92%
ROCE
25.44%
EPS (TTM)
$5.18
Investment Returns
1 Week
4.03%
1 Month
5.71%
3 Months
0.39%
6 Months
27.67%
9 Months
25.87%
Financials
Quarterly
All values in $ Mn
646.9
Mar 25
618.8
Jun 25
624.9
Sep 25
639.3
Dec 25
657.5
Mar 26
673.3
Jun 26
Updates
17Sep
Chemed subsidiary Roto-Rooter acquires largest franchise for $60.6 million
Roto-Rooter Services acquires largest independent franchise for $60.6 million. Deal covers California territories serving approximately 11 million people. Franchise generated $50.0 to $55.0 million annual revenue prior to acquisition. Transaction consolidates Chemed's footprint in Northern and Central California.
1mo ago
7Aug
Chemed Corp raises quarterly dividend by 17% to 70 cents
Chemed Corp declared a 70-cent quarterly dividend, up 17% from June. Payable Sept 3, it marks the 221st consecutive payout. The firm operates VITAS Healthcare and Roto-Rooter.
2mo ago
29Jul
Chemed raises FY26 adj EPS guidance to $25.00-$25.75 vs $24.34 estimate
Chemed Corporation raises full-year 2026 adjusted EPS guidance to $25.00-$25.75, exceeding the $24.34 analyst estimate. The revision is supported by Q2 GAAP EPS growth of 43.7% to $5.13, driven by VITAS Healthcare's 11.9% revenue increase and significantly lower Medicare Cap billing limitations.
3mo ago
21Jul
Barington pushes Chemed for strategic review, cost cuts
Activist investor Barington Capital Group is pressing Chemed to conduct a strategic review and implement cost cuts to boost shareholder value. The demands aim to address operational inefficiencies and optimize business segments. Chemed has not yet publicly responded to the proposal.
3mo ago
9Jul
B of A Securities raises Chemed price target to $510
B of A Securities analyst Joanna Gajuk maintained a Neutral rating on Chemed and raised the price target to $510 from $450, signaling a higher valuation outlook.
3mo ago
1Jul
Chemed Corporation to report Q2 2026 earnings on July 28
Chemed Corporation will release its Q2 2026 financial results on July 28, 2026, followed by a conference call on July 29, 2026, to discuss performance and business updates. The call will be accessible via webcast and teleconference, with a replay available afterward.
